NBRV News and Press, Nabriva Therapeutics plc From 09/09/21

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered i...

Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partne...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroed...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2021 Q2 earnings call. For further details see: Nabriva Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation

Nabriva Therapeutics plc (NBRV) Q2 2021 Results Conference Call August 5, 2021 4:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Conference Call Participants Suji Jeong - Jefferies Presentation Operator Good day, and thank you for stan...

Sphere 3D Corp (NASDAQ:ANY) +43% agreement to acquire exclusive rights for assignment of cryptocurrency mining assets Kaixin Auto (NASDAQ:KXIN) +23% on foraying into new energy vehicle business Switch (NYSE:SWCH) +19% on Q2 earnings Westport Fuel (NASDAQ:WPRT) +1...

Nabriva Therapeutics (NASDAQ:NBRV): Q2 GAAP EPS of -$0.29 beats by $0.06. Revenue of $8.24M vs $0.49M in Q220; beats by $2.25M. Press Release For further details see: Nabriva Therapeutics EPS beats by $0.06, beats on revenue

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd...

Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire WASHINGTON , Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of c...